Neonatal Hyperbilirubinemia
Customize your policy alerts
Sign up for Aetna Policy 0332 alerts
Get alerted when Policy 0332 changes without checking for updates manually.
Monitor payer policy activity
This Aetna clinical policy bulletin defines medical necessity criteria for assessment and treatment of neonatal hyperbilirubinemia (including phototherapy, exchange transfusion, G6PD testing, home phototherapy) and lists interventions considered experimental/investigational. It applies to neonatal/pediatric providers treating newborn jaundice.
No material clinical or coverage changes in this revision.
Medical Necessity and Coverage Criteria
Primary medical necessity criteria
Assessment and treatment considered medically necessary when the following criteria are met:
Prophylactic phototherapy is medically necessary for rapid rise in bilirubin (>1 mg/dL/hour) or as a temporary measure pending exchange transfusion.
Home Phototherapy
Home phototherapy is covered when ALL of the following criteria are met:
If bilirubin levels do not stabilize (+/- 1 mg/dL) or decline, more intensive phototherapy may be warranted.
Criteria for discontinuation of phototherapy
Phototherapy may be discontinued when the criteria below are met:
Preterm Infants
Preterm infants require modified phototherapy initiation and monitoring:
Preterm defined as <37 weeks gestation; consider complications (e.g., asphyxia, hypoxia, hemolysis) when assessing risk.
Clofibrate
Evidence summary and coverage context for clofibrate as an adjunct to phototherapy:
Larger, geographically diverse trials with safety and long-term outcomes are needed.
Zinc supplementation
Evidence summary and coverage position for oral zinc supplementation:
Trials were heterogeneous in dose (5–20 mg/day), duration, and populations; insufficient evidence for standard care.
Probiotics / Prebiotics
Evidence summary for enteral probiotics and prebiotics in prevention or treatment:
Some meta-analyses pooled 645–1,761 infants across trials; GRADE assessments indicate low-quality evidence.
Massage therapy
Evidence summary and policy position for massage therapy:
Limited data in preterm infants; further rigorous trials required.
Transcutaneous bilirubin devices
Guidance on transcutaneous bilirubin (TcB) device use and limitations during/after phototherapy:
UpToDate also states TcB is not reliable in infants undergoing phototherapy.
Exchange transfusion and phototherapy indications
Covered clinical actions and indications summarized from evidence:
Initiation thresholds should be applied in the context of infant age in hours and neurotoxicity risk factors per AAP guidance.
Adjunctive therapies (prebiotics/probiotics, clofibrate, metalloporphyrins, UDCA)
Evidence summaries for adjunctive therapies evaluated as supplements to phototherapy:
Cochrane and systematic reviews summarized.
Cochrane reviews and evidence-based reviews cited.
Most UDCA studies excluded preterm neonates and those with significant hemolysis.
Home-based and intermittent phototherapy
Evidence summary for alternative phototherapy delivery methods:
Home-based phototherapy requires appropriate eligibility and follow-up arrangements per policy.
Selection of intermittent versus continuous phototherapy should follow clinical judgment and available devices.
The policy identifies a set of interventions that are considered experimental/investigational and not covered because their effectiveness for neonatal hyperbilirubinemia has not been established. Examples listed include measurement of end-tidal carbon monoxide corrected for ambient CO (ETCOc), genotyping of BLVRA, SLCO1B1, and UGT1A1 for risk assessment, transcutaneous bilirubin (TcB) devices used while the infant is undergoing phototherapy, metalloporphyrins (e.g., tin mesoporphyrin), antenatal phenobarbital for isoimmunized pregnancies, zinc supplementation, massage therapy, prebiotics/probiotics, and ursodeoxycholic acid (UDCA) as an adjuvant to phototherapy.
Multiple systematic reviews and randomized trials of oral zinc (various doses and formulations) have not demonstrated a consistent reduction in the incidence of neonatal hyperbilirubinemia or need for phototherapy. Although some trials reported a shortened duration of phototherapy, pooled reviews concluded the evidence is limited, heterogeneous, and does not support routine use. An UpToDate treatment review also does not list zinc as a management option. Accordingly, routine oral zinc supplementation is not supported and is considered investigational for prevention of neonatal hyperbilirubinemia.
Systematic reviews of ursodeoxycholic acid (UDCA) as an adjunct to phototherapy report methodological limitations and important population exclusions. Notably, the primary studies largely excluded preterm neonates and neonates with significant hemolysis, and were conducted in limited geographic areas; pharmacokinetic and safety data in newborns are sparse. Therefore, the results from these trials cannot be generalized to preterm or hemolytic neonates, limiting applicability of UDCA in those populations.
This Clinical Policy Bulletin is provided as a general description to assist in administering plan benefits and clinical decision-making. It does not constitute a contract, guarantee coverage, or provide medical advice. Providers remain responsible for treatment decisions and should consult plan-specific coverage and prior authorization resources as appropriate.
Inpatient phototherapy or admission is typically reserved for infants who meet age- and risk-adjusted bilirubin thresholds. Per the policy, inpatient treatment may be considered medically necessary for healthy full-term infants with TSB ≥20 mg/dL in the first postnatal week, and may be medically necessary for preterm infants with TSB ≥18 mg/dL. Conversely, inpatient care is generally not medically necessary for healthy full-term infants with TSB <20 mg/dL or for preterm infants with TSB <18 mg/dL, as many of these infants can be managed with expectant observation or home phototherapy when other criteria are met.
Across systematic reviews and RCTs, available evidence does not support routine use of zinc supplementation to prevent neonatal jaundice. While isolated studies reported shorter phototherapy duration, overall results were inconsistent and meta-analyses did not show reductions in TSB at key time points or in incidence of hyperbilirubinemia. Therefore, zinc should not be used routinely as a preventive therapy for neonatal hyperbilirubinemia.
Systematic reviews of probiotics and prebiotics report some small trials showing reduced total serum bilirubin, shorter phototherapy duration, or decreased hospitalization, but the evidence is limited and of low quality. Current reviews conclude that these data are insufficient to recommend routine probiotic or prebiotic use for prevention or treatment of neonatal jaundice; larger, well‑designed randomized trials are needed before routine adoption.
Procedure, Drug and Diagnosis Codes
| P55.0 - P55.9 | Hemolytic disease of newborn |
| P57.0 - P57.9 | Kernicterus |
| P58.0 - P58.9 | Neonatal jaundice due to other excessive hemolysis |
| P59.0 - P59.9 | Neonatal jaundice from other and unspecified causes |
| O36.111+ - O36.199+ | Maternal care for other isoimmunization [not covered for the use of antenatal phenobarbital in red cell isoimmunized pregnant women] |
| Z15.89 | Genetic susceptibility to other disease [G6PD deficiency] |
| Z83.49 | Family history of other endocrine, nutritional and metabolic diseases [G6PD deficiency] |
| Z84.81 | Family history of carrier of genetic disease [G6PD deficiency] |
Provider Requirements, Prior Authorization and Operational Guidance
Reference the Clinical Policy Bulletin
Providers should reference the Clinical Policy Bulletin (CPB) for neonatal hyperbilirubinemia (Aetna Clinical Policy 0332) when submitting claims or requesting services to ensure interventions (e.g., phototherapy, exchange transfusion, G6PD testing) meet documented medical necessity criteria and coding guidance.
- Reference CPB 0332 when documenting indications, TSB thresholds, risk factors, and follow-up plans
- Include relevant TSB values, age-in-hours, gestational age, and presence/absence of AAP risk factors in documentation
Step therapy — Phototherapy first-line
Step therapy: phototherapy is the first-line treatment for term and near-term infants per AAP guidance and this CPB. Pharmacologic or adjuvant therapies (e.g., clofibrate, zinc, ursodeoxycholic acid, metalloporphyrins) are considered investigational or have limited evidence and should not replace initial phototherapy. Exchange transfusion is reserved for infants meeting age-in-hours specific thresholds or who fail to respond to intensive phototherapy.
- Initiate phototherapy according to age-in-hours TSB thresholds and risk-factor stratification
- Do not use zinc or other adjuvant agents as a substitute for standard phototherapy; document rationale if used as adjunct
- Reserve exchange transfusion for TSB above exchange thresholds or non-response to intensive phototherapy — perform in NICU setting
Clinical Background and Evidence Summary
This policy adapts American Academy of Pediatrics guidance for neonatal hyperbilirubinemia. It summarizes phototherapy initiation and exchange transfusion thresholds using age-in-hours specific TSB tables adjusted for gestational age and presence of risk factors (isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, or albumin <3.0 g/dL). Phototherapy is the primary recommended therapy and exchange transfusion is reserved for infants exceeding age/TSB thresholds or those with evidence of acute bilirubin encephalopathy.
Definitions and Risk Factors
Policy Dates and Revision History
Policy last reviewed on 08/10/2023.
Policy originally became effective on 05/25/1999.
Next policy review scheduled for 03/28/2024.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.